Deconstructing Concepts of Student Satisfaction, Engagement and Participation in UK Higher Education

This thesis argues that established models of student satisfaction in higher education fail to take into account the contribution that students make towards their own learning and satisfaction and postulates a holistic model of student satisfaction. This thesis also highlights that student satisfaction is a slow and incremental process spread over several semesters and thus can more appropriately be understood longitudinally. Based on the conceptual framework, a theoretical model is presented and empirically explored using two datasets: a cross-sectional dataset comprised of 147 students and a longitudinal dataset comprised of 66 students. Both datasets were collected from students at Oxford Brookes University. The longitudinal data is collected for 2 years (4 semesters). A theoretical model is presented and tested for empirical support using structural equation modelling (SEM) for the cross-sectional dataset while SEM growth curve modelling is employed to analyse the longitudinal dataset. The results provide overwhelming support for the proposed theoretical model and confirm that student satisfaction is indeed a multi-faceted concept and cannot be understood solely on aspects of student learning experiences like many established models. It can more appropriately be understood using other concepts that signify the contribution of students in their own learning and satisfaction such as student engagement and student participation. The results also point out the significance of understanding student satisfaction longitudinally and give an insight into students’ growth trajectories as well as their perceptions about student satisfaction at different times during their course

Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson's disease: a pharmacoinformatics study

Parkinson’s disease (PD) is caused by loss in nigrostriatal dopaminergic neurons and is ranked as the second most common neurodegenerative disorder. Dopamine receptor D3 is considered as a potential target in drug development against PD because of its lesser side effects and higher degree of neuro-protection. One of the prominent therapies currently available for PD is the use of dopamine agonists which mimic the natural action of dopamine in the brain and stimulate dopamine receptors directly. Unfortunately, use of these pharmacological therapies such as bromocriptine, apomorphine, and ropinirole provides only temporary relief of the disease symptoms and is frequently linked with insomnia, anxiety, depression, and agitation. Thus, there is a need for an alternative treatment that not only hinders neurodegeneration, but also has few or no side effects. Since the past decade, much attention has been given to exploitation of phytochemicals and their use in alternative medicine research. This is because plants are a cheap, indispensable, and never ending resource of active compounds that are beneficial against various diseases. In the current study, 40 active phytochemicals against PD were selected through literature survey. These ligands were docked with dopamine receptor D3 using AutoDock and AutoDockVina. Binding energies were compared to docking results of drugs approved by the US Food and Drug Administration against PD. The compounds were further analyzed for their absorption, distribution, metabolism, and excretion-toxicity profile. From the study it is concluded that glycyrrhetinic acid and E.resveratroloside are potent compounds having high binding energies which should be considered as potential lead compounds for drug development against PD

Kinetics of exoglucanase and endoglucanase produced by Aspergillus niger NRRL 567

In this study we reported for the first time kinetics of exoglucanase (EXG) and endoglucanase (EG) from Aspergillus niger NRRL 567. The optimum pH and temperature for crude EXG and EG was found to be 3.5 and 30°C respectively. Zn2+, Ca2+, Mn2+ and Co2+ enhanced the crude activity of EXG and EG whereas Mg2+, Fe2+ and Hg2+ showed various degree of inhibitory effects. Cu2+ enhanced crude EXG activity and inhibited crude EG activity. The energy of activation (Ea) for the EXG and EG were 21.20 and 22.52 kJ mol-1, respectively. The Q10 values obtained for the EXG and EG were 1.38 and 1.4, respectively. These enzymes had lower Km value that shows their high affinity for the substrates. Overall, the studies demonstrate that these enzymes may be suitable for industrial use.Key words: Exoglucanase, endoglucanase, kinetics, characterization, Aspergillus niger NRRL 567

Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson's disease: a pharmacoinformatics study

Parkinson’s disease (PD) is caused by loss in nigrostriatal dopaminergic neurons and is ranked as the second most common neurodegenerative disorder. Dopamine receptor D3 is considered as a potential target in drug development against PD because of its lesser side effects and higher degree of neuro-protection. One of the prominent therapies currently available for PD is the use of dopamine agonists which mimic the natural action of dopamine in the brain and stimulate dopamine receptors directly. Unfortunately, use of these pharmacological therapies such as bromocriptine, apomorphine, and ropinirole provides only temporary relief of the disease symptoms and is frequently linked with insomnia, anxiety, depression, and agitation. Thus, there is a need for an alternative treatment that not only hinders neurodegeneration, but also has few or no side effects. Since the past decade, much attention has been given to exploitation of phytochemicals and their use in alternative medicine research. This is because plants are a cheap, indispensable, and never ending resource of active compounds that are beneficial against various diseases. In the current study, 40 active phytochemicals against PD were selected through literature survey. These ligands were docked with dopamine receptor D3 using AutoDock and AutoDockVina. Binding energies were compared to docking results of drugs approved by the US Food and Drug Administration against PD. The compounds were further analyzed for their absorption, distribution, metabolism, and excretion-toxicity profile. From the study it is concluded that glycyrrhetinic acid and E.resveratroloside are potent compounds having high binding energies which should be considered as potential lead compounds for drug development against PD

Corn stover-enhanced cellulase production by Aspergillus niger NRRL 567

The production of extracellular cellulases by Aspergilus niger NRRL 567 on corn stover was studied in liquid state fermentation. In this study, three cellulases, exoglucanase (EXG), endoglucanase (EG) and β-glucosidase (BGL) were produced by A. niger NRRL 567. The optimal pH, temperature and incubation time for cellulases production was found to be 3.5, 30°C and 96 h, respectively. Maximal cellulases activities were achieved with 4% corn stover, 0.1% molasses and 1% yeast sludge. To our knowledge, this is the first report on production of cellulases by using corn stover as a substrate from A. niger NRRL 567.Key words: Corn stover, yeast sludge, cellulases, Aspergi l lus niger

The effect of mesoporous silica impregnation on tribo-electrification characteristics of flurbiprofen

Tribo-electrification is a common occurrence within the pharmaceutical industry where solid dosage forms constitute majority of pharmaceutical formulations. Tribo-electrification of powders leads to a range of complications such as adhesion of particulate material to the processing equipment resulting in segregation, affecting the content uniformity. Flurbiprofen, a highly charging material, was used as a model drug to investigate the tribo-electrification and adhesion characteristics by impregnating the model drug inside a mesoporous silica matrix. The model drug was impregnated using i) solvent loading, and ii) physical mixing methods, at varying degree of silica to drug ratio (5-20% w/w). The resulting mixtures were tribo-charged using a custom built device based on a shaking concept inside a stainless steel capsule, consisting of a Faraday cup and connected to electrometer. The electrostatic charge and the percentage adhesion of Flurbiprofen were reduced in both drug loading methods. The solvent impregnation method using acetone was more successful at reducing the electrostatic charge build up on flurbiprofen than physical powder mixing. The percentage adhesion to the shaking capsule was reduced notably as a result of loading the drug in the SBA-15 porous network. The results illustrate that the incorporation of highly charged model drug inside a low-charging pharmaceutical carrier system to be an effective approach in control the induction of tribo-electrification phenomena during powder processing

Influence of pH on mechanical relaxations in high solids lm-pectin preparations

The influence of pH on the mechanical relaxation of LM-pectin in the presence of co-solute has been investigated by means of differential scanning calorimetry, ζ-potential measurements and small deformation dynamic oscillation in shear. pH was found to affect the conformational properties of the polyelectrolyte altering its structural behaviour. Cooling scans in the vicinity of the glass transition region revealed a remarkable change in the viscoelastic functions as the polyelectrolyte rearranges from extended (neutral pH) to compact conformations (acidic pH). This conformational rearrangement was experimentally observed to result in early vitrification at neutral pH values where dissociation of galacturonic acid residues takes place. Time-temperature superposition of the mechanical shift factors and theoretical modeling utilizing WLF kinetics confirmed the accelerated kinetics of glass transition in the extended pectin conformation at neutral pH. Determination of the relaxation spectra of the samples using spectral analysis of the master curves revealed that the relaxation of macromolecules occurs within ~0.1 s regardless of the solvent pH

Elucidation of the controlled-release behavior of metoprolol succinate from directly compressed xanthan gum-chitosan polymers: computational and experimental studies

The development and evaluation of a controlled-release (CR) pharmaceutical solid dosage form comprising xanthan gum (XG), low molecular weight chitosan (LCS) and metoprolol succinate (MS) is reported. The research is, partly, based upon the utilization of computational tools; in this case molecular dynamics simulations (MDs) and response surface method (RSM), in order to underpin the design/prediction and to minimize the experimental work required to achieve the desired pharmaceutical outcomes. The capability of the system to control the release of MS was studied as a function of LCS (% w/w) and total polymer (LCS and XG) to drug ratio (P:D) at different tablet tensile strengths. MDs trajectories, obtained by using different ratios of XG:LCS as well as XG and high molecular weight CS (HCS), showed that the driving force for the interaction between XG and LCS is electrostatic in nature, the most favourable complex is formed when LCS is used at 15 % (w/w) and, importantly, that the interaction between XG and LCS is more favourable than that between XG and HCS. RSM outputs revealed that the release of the drug from the LCS/XG matrix is highly dependent on both the % LCS and the P:D ratio and that the required CR effect can be achieved when using weight fractions of LCS ≤ 20% and P:D ratios ≥ 2.6:1. Results obtained from in-vitro drug release and swelling studies on the prepared tablets showed that using LCS at the weight fractions suggested by MDs and RSM data plays a major role in overcoming the high sensitivity of the controlled drug release effect of XG on ionic strength and pH changes of the dissolution media. In addition, it was found that polymer relaxation is the major contributor to the release of MS from LCS-XG tablets. Using Raman spectroscopy, MS was shown to be localized more in the core of the tablets at the initial stages of dissolution due to film formation between LCS and XG on the tablet surface which prevents excess water penetration into the matrix. In the later stages of the dissolution process, the film starts to dissolve/erode allowing full tablet hydration and a uniform drug distribution in the swollen tablet

KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported. Methods The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAF V600E/K-mutated advanced melanoma from 22 sites in seven countries. Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day). Primary endpoint was PFS. Secondary endpoints were objective response rate, DOR, and OS. Efficacy was assessed in the intention-to-treat population, and safety was assessed in all patients who received at least one dose of study drug. This analysis was not specified in the protocol. Results Between November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy. With 36.6 months of follow-up, median PFS was 16.9 months (95% CI 11.3 to 27.9) with triplet and 10.7 months (95% CI 7.2 to 16.8) with doublet (HR 0.53; 95% CI 0.34 to 0.83). With triplet and doublet, respectively, PFS at 24 months was 41.0% (95% CI 27.4% to 54.2%) and 16.3% (95% CI 8.1% to 27.1%); median DOR was 25.1 months (95% CI 14.1 to not reached) and 12.1 months (95% CI 6.0 to 15.7), respectively. Median OS was not reached with triplet and was 26.3 months with doublet (HR 0.64; 95% CI 0.38 to 1.06). With triplet and doublet, respectively, OS at 24 months was 63.0% (95% CI 49.4% to 73.9%) and 51.7% (95% CI 38.4% to 63.4%). Grade 3-5 treatment-related adverse events (TRAEs) occurred in 35 patients (58%, including one death) receiving triplet and 15 patients (25%) receiving doublet. Conclusion In BRAF V600E/K-mutant advanced melanoma, pembrolizumab plus dabrafenib and trametinib substantially improved PFS, DOR, and OS with a higher incidence of TRAEs. Interpretation of these results is limited by the post hoc nature of the analysis